Status:
COMPLETED
Adrenal Artery Ablation for Primary Aldosteronism With Resistant Hypertension
Lead Sponsor:
Third Military Medical University
Conditions:
Resistant Hypertension
Eligibility:
All Genders
30-65 years
Phase:
NA
Brief Summary
Primary aldosteronism(PA) is the most common endocrine cause of resistant hypertension. Surgery and medicine are the main treatment for PA by the current guidelines. However,only a small part of patie...
Eligibility Criteria
Inclusion
- Male or female, age between 30-65 years old.
- Primary aldosteronism with resistant hypertension.
- Informed consent signed and agreed to participate in this trial.
Exclusion
- Secodary hyertension due to other causes.
- History of depression,schizophrenia or vascular dementia .
- History of cardio-cerebral vascular events such as congestive heart failure, myocardial infarction or stroke within 3 months.
- Hypohepatia (AST or AST is twice higher than the upper limit) or history of hepatitis or cirrhosis, hepatic encephalopathy.
- Renal insufficiency ( serum creatinine is 1.5 times higher than the upper limit) or history of dialysis and nephritic syndrome.
- Acute infections, tumor, severe arrhythmia, mental disorders, alcohol or medicine addiction.
- Fertile woman without contraceptives.
- Any surgical or medical conditions that significantly influence absorption, distribution, metabolism or excretion of the anti-hypertensive drugs.
- Allergic to or have contraindication to the contrast agents and alcohol.
Key Trial Info
Start Date :
October 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 15 2019
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT04345198
Start Date
October 1 2017
End Date
October 15 2019
Last Update
April 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The third hospital affiliated to the Third Military Medical University
Chongqing, China, 400042